Melanotan I
Also known as: Afamelanotide, Scenesse
Overview
Melanotan I is generally described as chemically identical to afamelanotide (Nle4-D-Phe7-α-MSH), which is FDA-approved as Scenesse since October 2019 specifically to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). That approval is specific to the Scenesse implant, its dosing and the EPP indication — it is not an approval for tanning or any other cosmetic use, and research-grade Melanotan I should not be assumed to be manufactured or quality-controlled to the same standard as the approved implant.
Last reviewed: September 2026
*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.
